Sugi Predict

Sugi Predict / Compounds / SCHEMBL5801169

SCHEMBL5801169

SCHEMBL5801169

Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCNCC1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 16/20 0.82
▸ LCK P06239 5/20 0.82
▸ LYN P07948 2/20 0.82
▸ NUDT14 O95848 2/20 0.76
▸ NUDT5 Q9UKK9 2/20 0.76
▸ SRC P12931 5/20 0.71
▸ TEK Q02763 2/20 0.71
▸ KDR P35968 1/20 0.71
▸ EGFR P00533 3/20 0.67
▸ ITK Q08881 2/20 0.65
▸ ABL1 P00519 1/20 0.65
▸ ERBB2 P04626 1/20 0.65
▸ FYN P06241 1/20 0.65
▸ YES1 P07947 1/20 0.65
▸ HCK P08631 1/20 0.65
▸ FGR P09769 1/20 0.65
▸ FER P16591 1/20 0.65
▸ CSK P41240 1/20 0.65
▸ TEC P42680 1/20 0.65
▸ BLK P51451 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21331506 0.99 BTK (0.81) BTKLCKLYNNUDT14NUDT5
SCHEMBL22737441 0.94 BTK (0.75) BTKLCKLYNNUDT14NUDT5
SCHEMBL6435508 0.94 BTK (0.75) BTKLCKLYNNUDT14NUDT5
SCHEMBL22720857 0.94 BTK (0.75) BTKLCKLYNNUDT14NUDT5
SCHEMBL30144776 0.94 BTK (0.75) BTKLCKLYNNUDT14NUDT5
SCHEMBL22720882 0.94 BTK (0.75) BTKLCKLYNNUDT14NUDT5
SCHEMBL5803386 0.94 BTK (0.76) BTKLCKLYNNUDT14NUDT5
SCHEMBL14576054 0.94 BTK (0.76) BTKLCKLYNNUDT14NUDT5
SCHEMBL30302001 0.92 BTK (0.79) BTKLCKLYNNUDT14NUDT5
SCHEMBL5804169 0.91 BTK (0.80) BTKLCKLYNNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 — — US claimed
EP-4745138-A1 THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-05-20 — — EP disclosed
CN-120202200-A Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof 标新生物医药科技(上海)有限公司 2025-06-24 — — CN disclosed
WO-2024245443-A1 COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-12-05 — — WO disclosed
CN-115611902-B Protein degradation compound designed based on Bruton tyrosine kinase ligand and application thereof 标新生物医药科技(上海)有限公司 2024-11-22 — — CN disclosed
US-12139492-B2 Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase ENDOTARGET INC. 2024-11-12 — — US disclosed
WO-2024175905-A1 DIMER COMPOUNDS Kesmalea Therapeutics Limited (GB) 2024-08-29 — — WO disclosed
CN-118027041-A BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-05-14 — — CN disclosed
CN-115304606-B Degradation agent for simultaneously targeting BTK and GSPT proteins 清华大学 2024-04-19 — — CN disclosed
US-20240100172-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY PAQ Therapeutics Inc. 2024-03-28 — — US disclosed
US-20140221398-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-08-07 — — US disclosed
US-20140221398-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-08-07 — — US disclosed
EP-1385524-A4 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2006-02-01 — — EP disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 — — US disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN BTK 42/4885LCK 1/4885LYN 72/4885
US-12139492-B2 Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase BTK, BCL6B, BCL9 BTK 1/4885LCK 10/4885LYN 7/4885
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN BTK 1/4885LCK 20/4885LYN 10/4885
US-20140221398-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS BMX, BLK, TEC BTK 5/4885LCK 14/4885LYN 24/4885
US-20240100172-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, SQSTM1, BECN1 BTK 3766/4885LCK 3934/4885LYN 3291/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 BTK 1020/4885LCK 1011/4885LYN 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.